N

New Jersey Hematology Oncology Associates | Brick Office

Research site

(Unclaimed)

Location

1608 Route 88 West Suite 250, Brick, New Jersey, United States of America

Site insights

Top conditions

Top treatments

Ruxolitinib

Parsaclisib

Azacitidine

Atezolizumab

Trastuzumab

Ibrutinib

Inavolisib

nivolumab

Alectinib

Decitabine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 18 total trials

A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

This is a Phase II, randomized, multi-center, multinational, open-label, cross-over study in adult participants with PD-L1-positive NSCLC. Two popula...

Active, not recruiting

Non-small Cell Lung Cancer

Drug: Atezolizumab

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

The primary objectives of this study are to assess: (1) whether the combination of BP1001 plus venetoclax plus decitabine provides greater efficacy (...

Enrolling

Acute Myeloid Leukemia (AML)

Drug: BP1001 plus decitabine

Drug: BP1001 in combination with Ventoclax plus decitabine

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (PANTHER)

The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared wi...

Active, not recruiting

Leukemia, Myeloid, Acute

Leukemia, Myelomonocytic, Chronic

Drug: Pevonedistat

Drug: Azacitidine

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in particip...

Active, not recruiting

Post Polycythemia Vera Myelofibrosis

Myelofibrosis

Drug: parsaclisib

Drug: placebo